Zusammenfassung
Oral applizierte Probiotika wurden in den letzten Jahren sowohl zur Prävention als auch zur Therapie der atopischen Dermatitis eingesetzt, da sich aus theoretischen Überlegungen und aus experimentellen Beobachtungen im Tiermodell potenzielle Effekte vermuten ließen. Wie in diesem Übersichtsbeitrag näher dargestellt, kann man aus den Therapiestudien die eindeutige Empfehlung ableiten, dass die atopische Dermatitis, egal in welcher Ausprägung, keine Indikation zur Therapie mit oralen Probiotika darstellt. In Präventionsstudien wurde zunächst aus Finnland ein deutlicher Effekt von Laktobazillen berichtet, die schwangeren Frauen und Neugeborenen oral appliziert worden waren. Allerdings ließen sich diese positiven Ergebnisse von anderen Arbeitsgruppen nicht reproduzieren. Solange die Rolle der Einflussfaktoren auf die Ergebnisse nicht zu klären ist, kann keine Empfehlung zur Gabe von Probiotika zur Prävention der atopischen Dermatitis ausgesprochen werden, wie auch in der aktuellen deutschen S3-Leitlinie zur Allergieprävention ausgeführt wird.
Abstract
Orally administered probiotics have been employed for the prevention and therapy of atopic dermatitis in recent years, because both theoretical considerations and animal models suggested positive effects were likely. Current clinical studies make it clear that oral probiotics are not indicated for the therapy of mild, moderate or severe atopic dermatitis. A prevention study from Finland described a marked positive effect of lactobacilli on the rate of atopic dermatitis when the bacteria were given orally to the pregnant mother and the newborn. However, these positive results could not be reproduced by other investigators. Until these varying results are explained, no recommendation can be made for use of oral probiotics to prevent atopic dermatitis, as is stated in the current German S3 guideline on the prevention of allergies.
Literatur
Abrahamsson TR, Jakobsson T, Bottcher MF et al (2007) Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 119:1174–1180
Fölster-Holst R, Muller F, Schnopp N et al (2006) Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 155:1256–1261
Gore C, Munro K, Lay C et al (2008) Bifidobacterium pseudocatenulatum is associated with atopic eczema: a nested case-control study investigating the fecal microbiota of infants. J Allergy Clin Immunol 121:135–140
Gruber C, Wendt M, Sulser C et al (2007) Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy 62:1270–1276
Isolauri E, Arvola T, Sutas Y et al (2000) Probiotics in the management of atopic eczema Clin Exp Allergy 30:1604–1610
Kalliomaki M, Salminen S, Arvilommi H et al (2001) Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357:1076–1079
Kalliomaki M, Salminen S, Poussa T et al (2003) Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 361:1869–1871
Kalliomaki M, Salminen S, Poussa T, Isolauri E (2007) Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol 119:1019–1021
Kopp MV, Hennemuth I, Heinzmann A, Urbanek R (2008) Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 121:850–856
Kukkonen K, Savilahti E, Haahtela T et al (2007) Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 119:192–198
Marschan E, Kuitunen M, Kukkonen K et al (2008) Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy 38:611–618
Pohjavuori E, Viljanen M, Korpela R et al (2004) Lactobacillus GG effect in increasing IFN-gamma production in infants with cow’s milk allergy. J Allergy Clin Immunol 114:131–136
Prescott SL, Dunstan JA, Hale J et al (2005) Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy 35:1557–1564
Prescott SL, Dunstan JA, Hale J et al (2005) Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy 35:1557–1564
Rosenfeldt V, Benfeldt E, Nielsen SD et al (2003) Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 111:389–395
Salminen MK, Tynkkynen S, Rautelin H et al (2002) Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35:1155–1160
Sawada J, Morita H, Tanaka A et al (2007) Ingestion of heat-treated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/Nga mice. Clin Exp Allergy 37:296–303
Schäfer T, Kopp M, Reese I et al (2009) S3 Leitlinie Allergieprävention-Update 2009. Allergo J 18:332–341
Sepp E, Julge K, Mikelsaar M, Bjorksten B (2005) Intestinal microbiota and immunoglobulin E responses in 5-year-old Estonian children. Clin Exp Allergy 35:1141–1146
Sistek D, Kelly R, Wickens K et al (2006) Is the effect of probiotics on atopic dermatitis confined to food sensitized children? Clin Exp Allergy 36:629–633
Smits HH, Engering A, van der Kleij D et al (2005) Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 115:1260–1267
Taylor AL, Dunstan JA, Prescott SL (2007) Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol 119:184–191
Taylor AL, Hale J, Hales BJ et al (2007) FOXP3 mRNA expression at 6 months of age is higher in infants who develop atopic dermatitis, but is not affected by giving probiotics from birth. Pediatr Allergy Immunol 18:10–19
Valtonen V, Järvinen A (2002) Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35:1155–1160
Viljanen M, Pohjavuori E, Haahtela T et al (2005) Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome. J Allergy Clin Immunol 115:1254–1259
Viljanen M, Savilahti E, Haahtela T et al (2005) Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 60:494–500
Werfel T, Aberer W, Augustin M et al (2009) Neurodermitis: S2 Leitlinie. J Dtsch Dermatol Ges Suppl 1:S1–S46
Weston S, Halbert A, Richmond P, Prescott SL (2005) Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child 90:892–897
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Werfel, T. Inside-Out. Hautarzt 60, 802–808 (2009). https://doi.org/10.1007/s00105-009-1756-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-009-1756-7